FAVOR II Europe-Japan FAVOR II E-J

Slides:



Advertisements
Similar presentations
Disclosure Statement of Financial Interest
Advertisements

BIFURCATION LESIONS Dr. Tahsin.N
PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY ON THE MANAGEMENT OF INTERMEDIATE CORONARY STENOSES: The Functional or morphological Lesion Assessment for.
FFR vs Angiography for Multivessel Evaluation
To stent or not to stent Clinical Utility of Fractional Flow Reserve.
TOTAL Culprit lesion thrombus burden after manual aspiration thrombectomy or PCI alone in STEMI The OCT Substudy of the TOTAL (ThrOmbecTomy versus PCI.
The BHF FAMOUS NSTEMI Trial For the FAMOUS NSTEMI Investigators ESC Hotline for Myocardial Infarction, 1 Sep 2014 J. Layland, K.G. Oldroyd, N. Curzen,
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.
PRIMARY Results of ADVISE ADenosine Vasodilation Independent Stenosis Evaluation Dr Justin Davies MD, PhD Imperial College London on behalf of the ADVISE.
BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.
Elective Stenting versus Balloon Angioplasty with Bail-out Stenting for Small Vessel Coronary Artery Disease: Evidence from a Meta-analysis of Randomized.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
PLATFORM: Economic and Quality of Life Outcomes of an FFR CT Diagnostic Strategy in Suspected CAD Mark A Hlatky, Bernard De Bruyne, Gianluca Pontone, Manesh.
Determination of the RAdial versus GrOiN coronary angioplasty The Result of DRAGON Trial Shigeru Saito, MD Department of Cardiology and Catheterization.
PLATFORM: Economic and Quality of Life Outcomes of an FFR CT Diagnostic Strategy in Suspected CAD Mark A Hlatky, Bernard De Bruyne, Gianluca Pontone, Manesh.
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
Title of Presentation Presenter Name, Designation Presenter 2 Name, Designation Presenter 3 Name, Designation.
CIT 2016 Template Title 40 pt Bold Arial David Liu, MD Subtitle 34 pt Arial Bold Italics.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
J Hermiller MD 1 Bifurcation Lesion Treatment Option: Insights From Clinical Literature James Hermiller, MD, FACC, FSCAI St Vincent Medical Group St Vincent.
Strategies to Improve Inadequate Guide Catheter Support John S Douglas Jr MD S Tanveer Rab MD Emory University School of Medicine Atlanta Georgia Sunday.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
J Am Coll Cardiol 2008;52:636–43 Comprehensive Assessment of Coronary Artery Stenoses Computed Tomography Coronary Angiography Versus Conventional Coronary.
Martin B. Leon, MD Key Messages Tryton Pivotal: Randomized Trial and
Simplifying Serial Lesion Assessment
Leveraging Bayesian Methodology to Increase the Trial Efficiency
David E. Kandzari, MD on behalf of the BIONICS investigators
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Nico H.J. Pijls, William F. Fearon, Peter Jüni, and Bernard De Bruyne
Updates From NOTION: The First All-Comer TAVR Trial
Quantitative Flow Ratio (QFR)
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
BRS Next Large Trials: What is on the Horizon?
Emerging FFR Non-Wire-based Technology
ADenosine Vasodilator Independent Stenosis Evaluation II
Surgical Mitral Valve Repair: What is the Gold Standard?
Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s COMBO StEnt Japan-USA HARMONEE: Primary Report of A Randomized Trial of a Bioabsorbable.
Disclosure Statement of Financial Interest
9:00 AM-9:05 AM, Tuesday, Oct. 31; Room 201/203
Background Over PCIs per year for stable angina
The Tryton Bifurcation Trial:
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Main Arena II, Tuesday, Oct. 31, First Report Investigations 2
TCT 2016, Washington convention center
OCT-Guided PCI What needs to be done to establish criteria?
Preliminary results of the Elutax SV Italian registry
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS,
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.
Angiography-guided PCI
A Randomized, Prospective, Intercontinental Evaluation of a Bioresorbable Polymer Sirolimus-eluting Stent: the CENTURY II Trial: an Update with 2 Years.
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
FAMOUS-NSTEMI Trial design: Participants with NSTEMI were randomized to an FFR-guided strategy (n = 176) vs. a coronary angiography-guided strategy (n.
Bjarne L. Nørgaard et al. JACC 2018;72:
Nat. Rev. Cardiol. doi: /nrcardio
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
FFRangio Accuracy vs. STandard FFR: Results from the FAST-FFR Trial
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
Advanced Statistical Methods for Translational Research
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.
Disclosure Statement of Financial Interest
Disclosure Statement of Financial Interest
Javier Escaned et al. JCIN 2018;11:
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

FAVOR II Europe-Japan FAVOR II E-J Diagnostic Accuracy of On-line Quantitative Flow Ratio Functional Assessment by Virtual Online Reconstruction: FAVOR II Europe-Japan On behalf of the FAVOR II study group Jelmer Westra PCI Research Aarhus University Hospital, Skejby ● Denmark

Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Accuracy (%) Affiliation/Financial Relationship Company Grant/Research Support Consulting Fees/Honoraria Medis medical imaging bv. Funding The study was funded by Aarhus University Hospital, Skejby and participating institutions. Medis Medical Imaging bv. provided no funding for the study except limited travel arrangements for initiation and monitoring visits. The QFR solution was made available for free during the study period. SKEJBY PCI Research Aarhus University Hospital, Skejby ● Denmark Aarhus University Hospital FAVOR II Europe-Japan Jelmer.westra@clin.au.dk

Background FAVOR II E-J In patients with angina pectoris, evaluation of coronary stenosis by costly invasive pressure wire measurements is the present gold standard. In clinical practice, decision to treat a stenosis or not, is often based on angiographic evaluation. Quantitative flow ratio (QFR) is a computational method for emulating pressure wire measurements that has showed good agreement with the current gold standard Fractional flow reserve (FFR)* Feasibility and precision of QFR are unknown when performed during coronary angiography and in a multicenter setting. *Tu et al.; JACC Cardiovasc Interv 2016 Westra et al.; WIFI II, TCT 2016 SKEJBY PCI Research Aarhus University Hospital, Skejby ● Denmark Aarhus University Hospital FAVOR II Europe-Japan Jelmer.westra@clin.au.dk

QFR analysis FAVOR II E-J QFR is an estimate of FFR based on: Accuracy (%) mm QFR is an estimate of FFR based on: 3-D reconstructions theoretical fluid dynamics QFR by Medis Suite, Medis medical imaging. CE-marked. Not approved for clinical use in the US. SKEJBY PCI Research Aarhus University Hospital, Skejby ● Denmark Aarhus University Hospital FAVOR II Europe-Japan Jelmer.westra@clin.au.dk

FAVOR II E-J Purpose To evaluate the feasibility and precision of in-procedure QFR compared to standard quantitative angiographic assessment with FFR as reference standard SKEJBY PCI Research Aarhus University Hospital, Skejby ● Denmark Aarhus University Hospital FAVOR II Europe-Japan Jelmer.westra@clin.au.dk

Primary endpoint FAVOR II E-J Sensitivity and specificity of : QFR compared to two-dimensional quantitative coronary angiography (2D-QCA) - in assessing functional stenosis relevance with FFR as reference standard SKEJBY PCI Research Aarhus University Hospital, Skejby ● Denmark Aarhus University Hospital FAVOR II Europe-Japan Jelmer.westra@clin.au.dk

Design FAVOR II E-J Investigator initiated study Observational study Both acquisition of FFR and computation of QFR in all patients Site specific protocol for effective blinding Strict protocol for QFR analysis More than one study vessel pr. patient allowed Planned enrolment of 310 patients to ensure at least 274 study vessel in the final analysis 11 hospitals in Europe and Japan Enrolment period: March 2017 to October 2017 SKEJBY PCI Research Aarhus University Hospital, Skejby ● Denmark Aarhus University Hospital FAVOR II Europe-Japan Jelmer.westra@clin.au.dk

Primary endpoint FAVOR II E-J QFR 2D-QCA Vessels (n=317) Sensitivity Specificity 88% (80-93) 88% (83-92) 46% (36-55) 77% (70-82) QFR 2D-QCA Comparisons by McNemar’s test SKEJBY PCI Research Aarhus University Hospital, Skejby ● Denmark Aarhus University Hospital FAVOR II Europe-Japan Jelmer.westra@clin.au.dk

Primary endpoint FAVOR II E-J FAVOR II E-J met the primary endpoint; Vessels (n=317) p<0.001 p<0.001 FAVOR II E-J met the primary endpoint; QFR was superior to standard quantitative angiographic diagnosis Sensitivity Specificity 88% (80-93) 88% (83-92) 46% (36-55) 77% (70-82) QFR 2D-QCA Comparisons by McNemar’s test SKEJBY PCI Research Aarhus University Hospital, Skejby ● Denmark Aarhus University Hospital FAVOR II Europe-Japan Jelmer.westra@clin.au.dk

Results – Time to QFR and FFR FAVOR II E-J Results – Time to QFR and FFR 4.8 m (IQR: 3.5-6.0) 7.0 m (IQR: 5.0-10.0) P=<0.001 SKEJBY PCI Research Aarhus University Hospital, Skejby ● Denmark Aarhus University Hospital FAVOR II Europe-Japan Jelmer.westra@clin.au.dk

Conclusion FAVOR II E-J QFR was superior to standard quantitative angiographic assesment for detection of stenosis requiring revascularization using FFR as reference standard QFR performed during coronary angiography was feasible and was computed within the time of standard FFR measurements Randomized trials are required to determine if a QFR based diagnostic strategy provides clinical outcome similar to pressure wire based strategies SKEJBY PCI Research Aarhus University Hospital, Skejby ● Denmark Aarhus University Hospital FAVOR II Europe-Japan Jelmer.westra@clin.au.dk